The growing number of private biopharma and diagnostic/therapeutic technology company financings completed in recent months masks an overall year-over-year decrease in the total value of those deals.
A look at the just-released 2Q 2019 PitchBook National Venture Capital Association (NVCA) Venture Monitor report detailing January–June 2019 activity showed a total $8.3 billion in 404 deals took place in the “pharma & biotech” sector. That’s a 14% drop in value from the $9.67 billion recorded during the first half of 2018, though the number of deals rose year-over-year from 317 in the first half of last year.
